[A17-31] Secukinumab (plaque psoriasis) - Addendum to Commission A17-08
Last updated 17.08.2017
Project no.:
A17-31
Commission:
Commission awarded on 11.07.2017 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Indication:
Adults with moderate to severe plaque psoriasis
Result of dossier assessment:
Conclusion of dossier assessment A17-08 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A17-08 | Secukinumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
Federal Joint Committee (G-BA)
2017-08-17 A G-BA decision was published.